These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32956731)

  • 1. The use of antimotility drugs in COVID-19 associated diarrhea.
    Kow CS; Hasan SS
    J Infect; 2021 Feb; 82(2):e19. PubMed ID: 32956731
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and CT imaging features of SARS-CoV-2 patients presented with diarrhea.
    Han J; Gong H; Fu L; Chen P; Wang S; Yuan J; Fu Z
    J Infect; 2020 Dec; 81(6):e33-e35. PubMed ID: 32768451
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the Editor in response to the article 'Candidate drugs against SARS-CoV-2 and COVID-19'.
    Campesi I; Montella A; Franconi F
    Pharmacol Res; 2021 Jan; 163():105285. PubMed ID: 33160068
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19".
    Mastellos DC; Lambris JD
    Clin Immunol; 2021 Jan; 222():108617. PubMed ID: 33115645
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.
    Tang M; Cai J; Tan J
    Med Clin (Barc); 2021 Jun; 156(11):576. PubMed ID: 33593637
    [No Abstract]   [Full Text] [Related]  

  • 6. Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19.
    Di Maria E; Martini P; Gennarelli M
    Pharmacol Res; 2021 Feb; 164():105402. PubMed ID: 33359911
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 and IBD drugs: should we change anything at the moment?
    Lees CW; Irving PM; Beaugerie L
    Gut; 2021 Apr; 70(4):632-634. PubMed ID: 33214164
    [No Abstract]   [Full Text] [Related]  

  • 8. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.
    Clementi N; Scagnolari C; D'Amore A; Palombi F; Criscuolo E; Frasca F; Pierangeli A; Mancini N; Antonelli G; Clementi M; Carpaneto A; Filippini A
    Pharmacol Res; 2021 Jan; 163():105255. PubMed ID: 33096221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real Asymptomatic SARS-CoV-2 Infection Might Be Rare: Importance of Careful Interviews and Follow-up.
    Jeong TH; Pak C; Ock M; Lee SH; Son JS; Jeon YJ
    J Korean Med Sci; 2020 Sep; 35(37):e333. PubMed ID: 32959547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID).
    Giollo A; Adami G; Gatti D; Idolazzi L; Rossini M
    Ann Rheum Dis; 2021 Feb; 80(2):e12. PubMed ID: 32321720
    [No Abstract]   [Full Text] [Related]  

  • 11. Ebselen, a new candidate therapeutic against SARS-CoV-2.
    Haritha CV; Sharun K; Jose B
    Int J Surg; 2020 Dec; 84():53-56. PubMed ID: 33120196
    [No Abstract]   [Full Text] [Related]  

  • 12. Are glomerular patients treated with immunosupressed drugs more protected against sever SARS-Covid -2?
    Agraz-Pamplona I; Montoro B; Bury R; Soler MJ; Carro CG; Solans R; Bolufer M; Cortes J; Espinel E; Seron D
    Semin Arthritis Rheum; 2020 Dec; 50(6):e4. PubMed ID: 32994058
    [No Abstract]   [Full Text] [Related]  

  • 13. The Inherent Unfairness of COVID-19 Drug Access Pathways.
    Spector-Bagdady K; Gravelin M; Weatherwax KJ; Shuman AG
    Am J Bioeth; 2020; 20(9):18-20. PubMed ID: 33505223
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo
    Monti S; Montecucco C
    Ann Rheum Dis; 2021 Feb; 80(2):e13. PubMed ID: 32354774
    [No Abstract]   [Full Text] [Related]  

  • 15. Administration of end-of-life drugs by family caregivers during covid-19: opportunity for future home prescribing plans.
    Julião M
    BMJ; 2020 Jun; 369():m2408. PubMed ID: 32554622
    [No Abstract]   [Full Text] [Related]  

  • 16. Update to living WHO guideline on drugs for covid-19.
    BMJ; 2021 Jul; 374():n1703. PubMed ID: 34230027
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse drug reactions in SARS-COV-2 hospitalised patients: a case series with a focus on drug-drug interactions-comment.
    Pardo-Cabello AJ; Manzano-Gamero V; Belda-Rustarazo S; Giner-Escobar P
    Intern Emerg Med; 2021 Apr; 16(3):797-798. PubMed ID: 33517559
    [No Abstract]   [Full Text] [Related]  

  • 18. Ivermectin for COVID-19: Promising but not yet conclusive.
    Van Rensburg R; Decloedt EH; Reuter H; Parker A; Schrueder N; Lahri S
    S Afr Med J; 2021 Jan; 111(3):13187. PubMed ID: 33944732
    [No Abstract]   [Full Text] [Related]  

  • 19. Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy.
    Finsterer J
    Acta Neurol Belg; 2021 Jun; 121(3):799-800. PubMed ID: 33225405
    [No Abstract]   [Full Text] [Related]  

  • 20. Persistence of intestinal SARS-CoV-2 infection in patients with COVID-19 leads to re-admission after pneumonia resolved.
    Wang X; Zhou Y; Jiang N; Zhou Q; Ma WL
    Int J Infect Dis; 2020 Jun; 95():433-435. PubMed ID: 32353545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.